2003

Mar 30, 2003
Guidant Reports Positive Six-Month Clinical Results of Everolimus Eluting Coronary Stent

Data Supports Use of Everolimus for Drug Eluting Stents Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease, today announced...

Mar 30, 2003
Guidant Announces Preliminary 30-Day Results of Study of Carotid Artery Stenting as Alternative Treatment for High Surgical-Risk Patients

Study Evaluates Potential New Minimally Invasive Treatment for Carotid Artery Disease Indianapolis, Ind. and Menlo Park, Calif. - Guidant Corporation (NYSE: GDT), a world leader in the treatment...

Mar 28, 2003
Guidant Reports Results of Preclinical Study of Stents for Treatment of Vulnerable Plaque

Study Evaluates Therapeutic Options for Preventing Heart Attacks Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease, today...

Mar 19, 2003
Guidant Signs Definitive Agreement to Acquire Biosensors' Everolimus Eluting Stent Assets

Company Updates Status of Drug Eluting Stent Program Webcast/Conference Call Scheduled for Thursday, March 20, at 11:00 AM ET Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader...

Mar 19, 2003
Guidant to Host Investor Briefing at American College of Cardiology Meeting

Live Webcast Available Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease, announced today that it will host an investor briefing...

Show 5102550100 per page
Top